<DOC>
	<DOC>NCT01506167</DOC>
	<brief_summary>This prospective, multi-center, observational study will assess the safety and efficacy of Avastin (bevacizumab) in daily practice in patients with metastatic colorectal cancer who have received no previous treatment for advanced disease and are receiving Avastin in combination with a standard of care first-line chemotherapy regimen. Data will be collected for 1.5 years or until death.</brief_summary>
	<brief_title>An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Metastatic colorectal cancer with no previous systemic treatment for advanced disease Receiving Avastin in combination with a firstline standard of care chemotherapy regimen Avastin initiated at the same time as firstline chemotherapy regimen Investigational, nonstandard of care firstline chemotherapy regimen for treatment of metastatic colorectal cancer Contraindication to Avastin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>